Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Pediatr Cardiol ; 45(3): 614-622, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38153548

ABSTRACT

Aspirin (ASA) remains the most common antiplatelet agent used in children. VerifyNow Aspirin Test® (VN) assesses platelet response to ASA, with therapeutic effect defined by the manufacturer as ≤ 549 aspirin reaction units (ARU). Single-center, observational, analysis of 195 children (< 18 years-old) who underwent first VN between 2015 and 2020. Primary outcome was proportion of patients with ASA biochemical resistance (> 549 ARU). Secondary outcomes included incidence of new clinical thrombotic and bleeding events during ≤ 6 months from VN in those who received ASA monotherapy (n = 113). Median age was 1.8 years. Common indications for ASA included cardiac anomalies or dysfunction (74.8%) and ischemic stroke (22.6%). Median ASA dose before VN was 4.6 mg/kg/day. Mean VN was 471 ARU. ASA biochemical resistance was detected in 14.4% (n = 28). Of 113 patients receiving ASA monotherapy, 14 (12.4%) had a thrombotic event and 2 (1.8%) had a bleeding event. Mean VN was significantly higher at initial testing in patients experiencing thrombotic event compared to those without thrombosis (516 vs 465 ARU, [95% CI: 9.8, 92.2], p = 0.02). Multivariable analysis identified initial VN ASA result ≥ 500 ARU at initial testing as the only significant independent risk factor for thrombosis (p < 0.01). VN testing identifies ASA biochemical resistance in 14.4% of children. VN ASA ≥ 500 ARU rather than ≥ 550 ARU at initial testing was independently associated with increased odds of thrombosis. Designated cut-off of 550 ARU for detecting platelet dysfunction by ASA may need reconsideration in children.


Subject(s)
Aspirin , Thrombosis , Adolescent , Child , Humans , Infant , Aspirin/adverse effects , Incidence , Platelet Aggregation Inhibitors/adverse effects , Risk Factors , Thrombosis/prevention & control , Thrombosis/drug therapy
2.
J Appl Lab Med ; 9(2): 305-315, 2024 03 01.
Article in English | MEDLINE | ID: mdl-38101950

ABSTRACT

BACKGROUND: Direct oral anticoagulants (DOACs) and fondaparinux with stable pharmacokinetics are commonly used anticoagulants for outpatient care. Due to the lack of monitoring requirements, drug-specific assays are not available in most hospital laboratories, but drug levels are needed in some urgent/emergency situations. This study describes the development of a qualitative screen for the presence of DOAC or fondaparinux using coagulation tests found in most laboratories. METHODS: The DOAC screen is composed of a heparin anti-Xa activity assay and thrombin time (TT) assay. The STA®-Liquid-Anti-Xa assay calibrated with Stago Multi Hep® and STA®-TT were run on STA-R Max® analyzers. The anti-Xa activity and TT assays were repeated 5 times in samples of commercially available calibrators and controls for each drug: fondaparinux, dabigatran, rivaroxaban, apixaban, and edoxaban. Statistical analysis and correlations were performed for anti-Xa activity and TT results for each drug and pooled normal plasma. RESULTS: A significant correlation was found between heparin-calibrated anti-Xa levels and fondaparinux, rivaroxaban, apixiban, and edoxaban (r2 = 0.99-1.0). Dabigatran showed a strong linear correlation (r2 = 0.99) with TT. Anti-Xa levels >0.3 IU/mL and TT >25 seconds were determined as cutoffs at our lab for the detection of clinically relevant drug levels of factor Xa inhibitor and direct thrombin inhibitor, respectively. CONCLUSIONS: Our study demonstrates that commonly available heparin anti-Xa activity and TT assays can be used to qualitatively detect DOACs and fondaparinux and provides a method to establish a qualitative interpretation.


Subject(s)
Anticoagulants , Pyridines , Rivaroxaban , Thiazoles , Humans , Anticoagulants/pharmacology , Dabigatran , Fondaparinux , Heparin
3.
Clin Transplant ; 37(11): e15087, 2023 11.
Article in English | MEDLINE | ID: mdl-37526562

ABSTRACT

INTRODUCTION: Pharmacokinetics of mycophenolic acid (MPA) display substantial interpatient variability, with up to 10-fold difference of exposure in individual patients under a fixed-dose regimen. MPA trough level (C0) monitoring is common in clinical practice but has not proven sufficiently informative in predicting MPA exposure or patient outcomes, especially in children. No limited sampling strategies (LSSs) have been generated from pediatric heart transplant (HTx) recipients to estimate MPA AUC. METHODS: Single-center, observational analysis of 135 de novo pediatric HTx recipients ≤21 years old who underwent MPA AUC between 2011 and 2021. RESULTS: Median age was 4 years (IQR .6-12.1). Median time from transplant to MPA AUC sampling was 15 days (IQR 11-19). MMF doses (mg or mg/day) had low, negative Pearson correlation coefficients (r) while doses adjusted for weight or body surface area had low correlation with Trapezoidal MPA AUC0-24 h (r = .3 and .383, respectively). MPA C0 had weak association (r = .451) with Trapezoidal MPA AUC0-24 h . LSS with two pharmacokinetic sampling time points at 90 (C3 ) and 360 (C5 ) min after MMF administration (estimated AUC0-24 h  = 32.82 + 4.12 × C3  + 11.53 × C5 ) showed strong correlation with Trapezoidal MPA AUC0-24 h (r = .87). CONCLUSION: MMF at fixed or weight-adjusted doses, as well as MPA trough levels, correlate poorly with MPA AUC0-24 h . We developed novel LSSs to estimate Trapezoidal MPA AUC from a large cohort of pediatric HTx recipients. Validation of our LSSs should be completed in a separate cohort of pediatric HTx recipients.


Subject(s)
Heart Transplantation , Mycophenolic Acid , Humans , Child , Young Adult , Adult , Mycophenolic Acid/therapeutic use , Immunosuppressive Agents/therapeutic use , Immunosuppressive Agents/pharmacokinetics , Drug Monitoring , Area Under Curve
4.
Am J Clin Pathol ; 159(1): 60-68, 2023 01 04.
Article in English | MEDLINE | ID: mdl-36351044

ABSTRACT

OBJECTIVES: Activated partial thromboplastin time (aPTT) is the primary test used to monitor intravenous (IV) direct thrombin inhibitors (DTIs) but has many limitations. The plasma diluted thrombin time (dTT) has shown better correlation with DTI levels than aPTT. This study compared dose-response curves for dTT and aPTT in pediatric patients receiving argatroban and bivalirudin. METHODS: A retrospective review of pediatric patients treated with argatroban (n = 45) or bivalirudin (n = 14) monitored with dTT and aPTT. RESULTS: The dTT assay was calibrated to report DTI concentrations in µg/mL for argatroban and bivalirudin with good analytic sensitivity and specificity. The dTT was fivefold more likely to show a stable dose-response slope than the aPTT (P < .0002; odds ratio, 4.9). For patients in whom both dTT and aPTT showed a significant correlation between dose and assay results, dTT had a higher average correlation factor compared with aPTT (P = .007). Argatroban dose-response slopes showed more inter- and intrapatient variation than bivalirudin (dose-response slope coefficient of variation, 132% vs 52%). CONCLUSIONS: The dTT assay was more likely to show a stable dose response and have a stronger correlation with DTI dose than aPTT. Argatroban shows more variation in dose response than bivalirudin.


Subject(s)
Antithrombins , Pipecolic Acids , Humans , Child , Antithrombins/pharmacology , Antithrombins/therapeutic use , Partial Thromboplastin Time , Thrombin Time , Blood Coagulation Tests , Pipecolic Acids/pharmacology , Pipecolic Acids/therapeutic use , Hirudins/pharmacology , Anticoagulants , Thrombin , Recombinant Proteins
5.
J Thromb Haemost ; 20(9): 2151-2158, 2022 09.
Article in English | MEDLINE | ID: mdl-35748322

ABSTRACT

Caring for children and adolescents with disorders of hemostasis and thrombosis (HAT) has become more specialized and requires a unique skill set that many providers are not able to obtain in standard pediatric hematology/oncology/bone marrow transplant fellowship training programs. The influx of numerous therapeutic advances and increasing medical complexity has expanded the need for experienced HAT providers and subspecialty collaboration in the inpatient setting due to the nuances in the management of patients with HAT complications and concerns. While there are data highlighting the benefits of an inpatient hemostasis, thrombosis, and anticoagulation management service in adult hospitals, there are limited pediatric data supporting such programs. In this article, we summarize the current practices of various pediatric institutions in the inpatient management of HAT patients and provide a consensus opinion for the development of a pediatric inpatient HAT service at tertiary care referral centers.


Subject(s)
Inpatients , Thrombosis , Adolescent , Adult , Child , Communication , Consensus , Hemostasis , Hospitals, Pediatric , Humans , Infant, Newborn , Referral and Consultation , Thrombosis/diagnosis , Thrombosis/therapy
6.
Pediatr Cardiol ; 39(5): 941-947, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29500504

ABSTRACT

Heparin is used to decrease the risk of thromboembolic complications during electrophysiology studies (EPS); however, there is wide practice variation and minimal evidence to guide heparin dosing, particularly in pediatric patients. This study retrospectively analyzed heparin dosing and response, measured via activated clotting time (ACT), in patients undergoing EPS and used these data (pre-protocol cohort, n = 40), as well as guidance from available literature to implement a standardized heparin protocol (phase 1, n = 43). We utilized quality improvement methodology to refine this protocol (phase 2, n = 40) to improve therapeutic heparin response. Prior to the protocol, patients achieved therapeutic ACT levels (250-350 s) only 35% of the time which improved to 60% during phase 1 (p < 0.05) and to 73% during phase 2 (p < 0.001 compared to pre-protocol). There were no thromboses or significant adverse events in any group. These results demonstrate the effectiveness of a standardized heparin protocol in achieving effective antithrombotic therapy during left-sided pediatric EPS.


Subject(s)
Anticoagulants/administration & dosage , Catheter Ablation/methods , Heparin/administration & dosage , Thromboembolism/prevention & control , Adolescent , Anticoagulants/pharmacokinetics , Child , Cohort Studies , Dose-Response Relationship, Drug , Electrophysiological Phenomena , Female , Heparin/pharmacokinetics , Humans , Male , Retrospective Studies , Whole Blood Coagulation Time , Young Adult
7.
Am J Cardiol ; 120(11): 2049-2055, 2017 Dec 01.
Article in English | MEDLINE | ID: mdl-28942941

ABSTRACT

Iron deficiency (FeD), with or without anemia, in adults with heart failure (HF) is associated with poor outcomes, which can be improved with replacement therapy. A similar therapeutic opportunity may exist for children; however, iron laboratory measurements and FeD have not been described in pediatric patients with HF. A single-center, retrospective study was conducted on 28 patients <21 years old with a diagnosis of dilated cardiomyopathy and HF who had iron laboratories (serum iron, iron saturation, and ferritin) performed. The mean (standard deviation) age at time of laboratory collection was 10.3 (5.5) years. Twenty-seven patients (96.4%) met the criteria for FeD. Serum iron and iron saturation were significantly associated with inpatient hospitalization, being on inotropic medications, or having stage D HF. Low-serum iron was associated with a higher left ventricular end-diastolic dimension and left ventricular end-systolic dimension z-score by echocardiography ((ß -2.58, 95% confidence interval [CI] -4.76, -0.40, p = 0.02) and (ß -2.43, 95% CI -4.70, -0.17, p = 0.04)), respectively. Low ferritin was associated with higher mortality (relative risk 0.29, 95% CI 0.12, 0.70, p = 0.006). In conclusion, FeD was common in this pediatric cohort with more advanced HF. Iron profile abnormalities were associated with worse HF severity and outcomes including mortality.


Subject(s)
Anemia, Iron-Deficiency/blood , Cardiomyopathy, Dilated/complications , Heart Failure/blood , Heart Ventricles/physiopathology , Iron Deficiencies , Ventricular Function, Left/physiology , Anemia, Iron-Deficiency/complications , Biomarkers/blood , Cardiomyopathy, Dilated/blood , Cardiomyopathy, Dilated/diagnosis , Child , Disease Progression , Echocardiography , Female , Ferritins/blood , Follow-Up Studies , Heart Failure/diagnosis , Heart Failure/etiology , Heart Ventricles/diagnostic imaging , Humans , Iron/blood , Male , Prognosis , Retrospective Studies , Stroke Volume
8.
J Allied Health ; 43(3): e45-52, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25194067

ABSTRACT

With the increased chronicity of HIV disease, people living with HIV/AIDS (PLWHA) may develop impairments during their lifetime that can be addressed with physical therapy (PT). This study surveyed PTs in Atlanta, Georgia, to determine their knowledge and beliefs regarding PT treatment of PLWHA. Results revealed that the majority of respondents encounter PLWHA in their practices, viewed PT as effective for treating HIV/AIDS-related impairments, and felt comfortable treating such impairments. While most PTs self-identified their knowledge of HIV/AIDS-related impairments as "competent," less than half correctly identified transmission routes. Most PTs indicated that they would like to have additional training in PT treatment for PLWHA. This further confirms the need for continuing education opportunities for PTs in the care of PLWHA.


Subject(s)
HIV Infections/therapy , Needs Assessment , Physical Therapy Modalities , Clinical Competence , Georgia/epidemiology , HIV Infections/epidemiology , HIV Infections/transmission , Health Care Surveys , Humans , Physical Therapy Modalities/standards , Physical Therapy Modalities/statistics & numerical data
9.
AJR Am J Roentgenol ; 195(3): 677-86, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20729446

ABSTRACT

OBJECTIVE: The purpose of this study is to evaluate the impact of extracolonic findings when screening is undertaken by CT colonography (CTC). MATERIALS AND METHODS: We performed a retrospective cohort study of patients completing a screening CTC from August 2003 to June 2006 at Walter Reed Army Medical Center. Extracolonic findings were categorized using a CTC reporting and data system that classifies findings as highly significant, likely significant, and insignificant. All final diagnoses, surgeries, malignancies, and costs of diagnostic radiology procedures were calculated for each category. RESULTS: Of 2,277 patients (mean +/- SD age, 59 +/- 11 years; 60% white; 56% male) undergoing CTC, extracolonic findings were identified in 1,037 (46%) patients, with 787 (34.5%) insignificant and 240 (11.0%) significant findings. Evaluation of significant findings generated 280 radiology procedures and 19 surgeries over a mean follow-up time of 19 +/- 10 months. The total cost of the radiology studies was $113,179; the studies added approximately $50 extra per patient. Seven high-risk lesions were identified (six extracolonic malignancies and one large aortic aneurysm) in patients with significant findings. CTC also identified six intracolonic malignancies and three adenomas with high-grade dysplasia. When considering extracolonic findings, CTC increased the odds of identifying high-risk lesions by 78% (nine intracolonic lesions vs 16 intracolonic plus extracolonic lesions; p = 0.0156). Of the 16 intracolonic and extracolonic high-risk lesions, 11 (69%) underwent curative resection, and 5 of 11 (44.4%) were extracolonic. CONCLUSION: CTC increased the odds of identifying high-risk lesions by 78%. CTC should be considered as an alternative to optical colonoscopy for colorectal cancer screening or as a onetime procedure to identify significant treatable intracolonic and extracolonic lesions.


Subject(s)
Colonography, Computed Tomographic/methods , Colorectal Neoplasms/diagnostic imaging , Early Detection of Cancer , Analysis of Variance , Colonography, Computed Tomographic/economics , Female , Humans , Incidental Findings , Male , Middle Aged , Radiographic Image Interpretation, Computer-Assisted , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...